Anti-fugetactic Agent Combination Therapy for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments are insufficient in targeting and eradicating tumors, especially large or metastasizing cancers, due to the fugetactic activity of chemokines like CXCL12 and IL-8, which repel immune cells from tumor sites, reducing the immune system's ability to target and eliminate tumors.
Innovation Solution
Combining an anti-fugetactic agent with additional anti-cancer therapies such as chemotherapy, radiotherapy, immunotherapy, or vaccine therapy to attenuate the fugetactic effect of chemokines, allowing immune cells and anti-cancer agents to better access and target tumors, thereby enhancing treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-fugetactic agents are used alone to treat tumors, then immune system function is restored to some extent, but treatment efficacy is insufficient to eradicate tumors in all patients
Solution Approach 1:
The patent combines anti-fugetactic agents with multiple anti-cancer therapies (chemotherapy, radiotherapy, immunotherapy, antibody therapy, cell therapy, vaccine therapy) into a composite treatment regimen. This merging of different therapeutic modalities addresses the insufficient efficacy of single-agent treatment by creating synergistic effects that enhance tumor eradication while maintaining immune system restoration.
2Ease of operation
If chemokines are present at high concentrations in tumors, then tumor cells can repel immune cells, but this creates a barrier preventing anti-cancer agents from accessing the tumor
Solution Approach 1:
The patent applies anti-fugetactic agents as a preliminary intervention to block or attenuate the fugetactic effect of chemokines before administering anti-cancer agents. This preliminary anti-action neutralizes the chemokine-mediated repulsion, thereby removing the barrier that prevents immune cells and anti-cancer agents from accessing the tumor site, and enabling subsequent therapies to reach their target effectively.
3Reliability
If combination therapy is used to enhance treatment efficacy, then tumor targeting improves, but treatment complexity increases
Solution Approach 1:
The patent employs anti-fugetactic agents as a universal preparatory component that can be combined with multiple different anti-cancer therapy types (chemotherapy, radiotherapy, immunotherapy, antibody therapy, cell therapy, vaccine therapy). This multi-functional approach allows a single anti-fugetactic agent to enhance the effectiveness of various treatment modalities, improving tumor targeting efficiency while managing complexity through a standardized combination strategy.
Data Source
AI summary
The invention described herein relates to methods and compositions for treating cancer in a patient or a tumor cell by administering an effective amount of an anti-fugetactic agent and an additional anti-cancer agent.